AlphaVax is currently focusing the commercial potential of its alphavaccine vector technology in cancer immunotherapy. The development of immunotherapeutic alphavaccines for the treatment of cancer is a rapidly expanding area in which AlphaVax intends to take a lead position in developing new treatment modalities.
To date, AlphaVax has successfully optimized the alphavaccine technology, developed a strategic intellectual property portfolio, a robust, scalable, manufacturing process, and has advanced five alphavaccine candidates into human clinical trials. From these initial trials, the vaccine vector platform has demonstrated a favorable safety profile while eliciting the desired vaccine-specific immune responses. The Company’s alphavaccine technology is the only alphavirus-based vector system to have advanced into clinical testing.
To translate scientific discovery into commercial success requires combining excellent science with effective development and commercialization, while satisfying stringent regulatory requirements. Our highly experienced vaccine development team brings substantial collective experience in process development, analytical methods, regulatory affairs, compliance, technology transfer, and manufacturing.